Merus N.V. Common Shares
MRUS Real Time Price USDRecent trades of MRUS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MRUS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
MRUS Revenue by Segment or Geography
New patents grants
-
Patent Title: Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene Mar. 11, 2025
-
Patent Title: Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer Jan. 14, 2025
-
Patent Title: Antibody that binds erbb-2 and erbb-3 Nov. 12, 2024
-
Patent Title: Methods and means for the production of ig-like molecules Oct. 22, 2024
-
Patent Title: Bispecific igg antibodies as t cell engagers Aug. 13, 2024
-
Patent Title: Pd-1 binding domains May. 28, 2024
-
Patent Title: Multivalent antibody Apr. 09, 2024
-
Patent Title: Binding molecules that inhibit cancer growth Mar. 26, 2024
-
Patent Title: Methods and means for the production of ig-like molecules Mar. 12, 2024
-
Patent Title: Antibody producing non-human animals Mar. 12, 2024
-
Patent Title: Clec12axcd3 bispecific antibodies and methods for the treatment of disease Jan. 16, 2024
-
Patent Title: Methods of treating a subject having an egfr-positive and/or erbb-3-positive tumor Nov. 21, 2023
-
Patent Title: Antibody producing non-human animals Oct. 17, 2023
-
Patent Title: Human cd3 binding antibody Aug. 29, 2023
-
Patent Title: Antibodies that modulate a biological activity expressed by a cell Aug. 22, 2023
-
Patent Title: Binding molecules that bind cd137 and pd-l1 Jun. 27, 2023
-
Patent Title: Binding molecules that modulate a biological activity expressed by a cell Jun. 06, 2023
-
Patent Title: Antibody producing non-human animals Jan. 24, 2023
-
Patent Title: Antibody producing non-human animals Sep. 20, 2022
-
Patent Title: Generation of binding molecules Aug. 09, 2022
-
Patent Title: Antibody that binds erbb-2 and erbb-3 Mar. 22, 2022
-
Patent Title: Antibody producing non-human animals Feb. 01, 2022
-
Patent Title: Antibody producing non-human mammals Apr. 06, 2021
-
Patent Title: Recombinant production of mixtures of antibodies Mar. 02, 2021
-
Patent Title: Antibodies that bind egfr and erbb3 Nov. 24, 2020
-
Patent Title: Methods and means for the production of ig-like molecules Aug. 25, 2020
-
Patent Title: Method for selecting a single cell expressing a heterogeneous combination of antibodies Jun. 02, 2020
-
Patent Title: Generation of binding molecules May. 12, 2020
-
Patent Title: Recombinant production of mixtures of antibodies Dec. 17, 2019
-
Patent Title: Bispecific igg antibodies as t cell engagers Jul. 23, 2019
-
Patent Title: Methods and means for the production of ig-like molecules Jul. 02, 2019
-
Patent Title: Methods and means for the production of ig-like molecules Jun. 25, 2019
-
Patent Title: Human cd3 binding antibody Apr. 23, 2019
-
Patent Title: Antibody producing non-human mammals Apr. 24, 2018
-
Patent Title: Antibody producing non-human mammals Apr. 17, 2018
-
Patent Title: Human cd3 binding antibody Mar. 13, 2018
-
Patent Title: Generation of binding molecules Mar. 06, 2018
-
Patent Title: Antibody producing non-human mammals Sep. 19, 2017
-
Patent Title: Methods and means for the production of ig-like molecules Sep. 12, 2017
-
Patent Title: Method for selecting a single cell expressing a heterogeneous combination of antibodies Aug. 22, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to MRUS
Recent picks made for MRUS stock on CNBC
ETFs with the largest estimated holdings in MRUS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MRUS stock a Buy, Sell, or Hold?
- What is the price target for $MRUS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MRUS stock?
- Who owns the most shares of $MRUS stock?
- What funds own $MRUS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MRUS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.